ORIGINAL

The Community Foundation
Serving the Counties of Riverside and San Bernardino

2013 S.L. Gimbel Foundation Fund Grant Application

Internal Use Only:
Grant: $15,000

20130711 20000

Organization / Agency Information

Organization/Agency Name: Nancy Yeary Women's Cancer Research Foundation (Formerly known as Women's Cancer Research Foundation		
Physical Address: 351 Hospital Road Suite 506	**City/State/Zip** Newport Beach, CA 92663	
Mailing Address: Same as above	**City/State/Zip**	
CEO or Director: John Paul Micha, M.D	**Title:** CEO/President	
Phone: (949) 642-5165	**Fax:** (949) 642-7157	**Email:** janet@gynoncology.com
Contact Person: Janet Rae	**Title:** Executive Director	
Phone: (949) 642-5165	**Fax:** (949) 642-7157	**Email:** janet@gynoncology.com
Web Site Address: women's cancerfoundation.com		**Tax ID:** 33-0865870

Program / Grant Information

Interest Area: ☐Health ☐Environment ☐Animal Protection ☐Education ☐Human Dignity

Program / Project Name: A Phase II Study of outpatient Paclitaxel Carboplatin and Metformin for advanced stage Epithelial Ovarian, Peritoneal and Fallopian Tube Cancer		
Amount of Grant Requested: $15,000	**Total Organization Budget:** $450,000	**Percentage of Organization's Total Budget used for Administration:** 10%
Purpose of Grant Request (one sentence): To assist in funding for gynecological cancer research		

Signatures

Board President / Chair: (please print) Robert Yeary	**Title:** Chairman
Signature: * See attached - Lives in Texas	**Date:**
CEO/Director: (please print) John Paul Micha, M.D.	**Title:** CEO/President
Signature: John Paul Micha MD	**Date:** 7/9/13

The Community Foundation
Serving the Counties of Riverside and San Bernardino

2013 S.L. Gimbel Foundation Fund Grant Application

Internal Grant #:

Organization / Agency Information

Organization/Agency Name: Nancy Yeary Women's Cancer Research Four (Formerly Known as Women's Cancer Research Foundation)

Physical Address: 351 Hospital Road Suite 506 City/State/Zip: Newport Beach, CA

Mailing Address: 351 Hospital Road Suite 506 City/State/Zip: Newport Beach, CA

CEO or Director: John Paul Micha, M.D. Title: CEO/President

Phone: (949) 642-5165 Fax: (949) 646-7157 Email: janet@gynoncol

Contact Person: Janet Rae Title: Executive Director

Phone: (949) 642-5165 Fax: (949) 646-7157 Email: janet@gynonco

Web Site Address: Women's cancer Foundation.com Tax ID: 33-08658

Program / Grant Information

Interest Area: ☒Health ☐Environment ☐Animal Protection ☐Education ☐Human D

Program / Project Name: A Phase II Study of outpatient Paclitaxel Carboplatin and Metformin for advanced stage Epithelio Ovarian, Peritoneal and Fallopian Tube Cancer

Amount of Grant Requested: $15,000

Total Organization Budget:

Percentage of Organization's Budget used for Administratio

Purpose of Grant Request (one sentence): To assist in funding for gynecological canc reseo

Signatures

Board President / Chair: (please print) Robert Yeary Title: Chairman

* Signature: [signature] Date: 7/8/2013

CEO / Director: (please print) Title:

I. Organization Background; Target Population:

A)The Women's Cancer Research Foundation (WCRF) was founded in 1999 with the express intent of conducting clinical trial research that would effectuate more promising and curative treatments for patients afflicted with a gynecologic malignancy (e.g., cancers of the ovary, uterus, and cervix). The WCRF was originally entitled Gynecologic Oncology Associates Charitable Foundation; the name was changed in 2004 to the Women's Cancer Research Foundation to more appropriately reflect the foundation's mission of improving gynecologic cancer cure rates. The WCRF accomplishes its goals by tirelessly seeking out novel chemotherapy trials that potentially confer curative benefits for their patients.

B) In the past three years, the WCRF completed the first clinical study evaluating Bevacizumab and Gemcitabine in combination with Paclitaxel and Carboplatin for the treatment of advanced ovarian cancer. Moreover, they published their experience with weekly Paclitaxel and Carboplatin in the treatment of advanced ovarian cancer. Consequently, the WCRF's cure rates have remained higher than the national average (Hoag Hospital Cancer Center Report, 2011). In 2012, the WCRF published 16 gynecologic cancer articles in medical journals; they have published approximately 100 papers since 2003.

C) One program the WCRF has recently instituted is the use of Emend (Merck & Co., Inc.) for the treatment of nausea and vomiting in newly diagnosed (i.e., first line treatment) gynecologic cancer patients undergoing chemotherapy. The aforementioned participants will originate from both Orange County (population 3,056,000) and Riverside County (population 2,240,000), the two primary geographic locations for whom the WCRF consistently serve.

II. Project Information

A) Statement of Need

In 2009, 84,155 women in the United States were diagnosed with a gynecologic cancer, 27,813 of whom died from their disease. In an attempt to improve cure rates, the WCRF strives to offer novel chemotherapy agents to their patients, many of whom would not otherwise have access to these promising therapies.

B) Project Goal, Objectives and Methodology

In the EMEND study involving 75 subjects, 50 patients will be randomly assigned to receive single dose (SD) IV fosaprepitant with an oral placebo and 25 patients will be randomly assigned to receive oral aprepitant and SD IV placebo (e.g., normal saline). The objective will be to determine if the treatment is effective at managing chemotherapy induced nausea and vomiting (CINV) in gynecologic cancer patients being treated with chemotherapy. The patients will be evaluated with respect to the frequency and duration of nausea and vomiting episodes. A vomiting episode is defined as 1 or more distinct episodes of emesis (expulsion of stomach contents through the mouth) or retches (an attempt to vomit that is bereft of stomach contents).

The EMEND study is a randomized estimation study comparing fosaprepitant and aprepitant for the treatment of CINV in gynecologic cancer patients who received chemotherapy. A complete response (no acute or delayed CINV and no use of rescue medication within 120 hours after the initiation of chemotherapy) will be the primary endpoint. Baseline characteristics (age, disease stage, disease subtype) will be presented to describe the patients treated in this study.

Objective 1: Calculating the proportion of patients reporting no vomiting during the five days following initiation of chemotherapy.

Objective 2: Calculating the overall complete response rate (no emetic episodes or rescue therapy) during the five days (120 hours) following the initiation of chemotherapy.

Both objectives will be achieved via Complete response is the primary endpoint; this is defined as no acute and delayed CINV and no rescue medication following cycle one of the patients' adjuvant chemotherapy. Patients will record their episodes of vomiting via the Functional Living Index-Emesis (FLIE). The FLIE assesses a 3-day recall period encompassing the acute phase (24 hours post-chemotherapy) and the first 2 days of the delayed phase of chemotherapy-induced emesis (CIE). The FLIE questionnaires will be completed on day 2, reflecting the acute effect of CINV on daily life activities during first 24 hours (1 day) following chemotherapy; patients who complete this inventory will also be assessed on day 5 to supply information on the delayed effects of CINV on daily living activities. Responses (complete response (CR) or no CR) will also be independently corroborated via the Common Terminology Criteria for Adverse Events (version 4.0).

The study was initiated in May 2013. Patient accrual and treatment will occur throughout May 2014. The patient analysis and study completion will occur throughout March and April of 2015.

3) The grant will benefit all eligible patients diagnosed with gynecologic cancer. The study will initially impact the 75 patients who will comprise the study subjects. However, ultimately, if the medication is effective at mitigating severe nausea and vomiting, the results may proffer significant clinical implications in terms of overall patient care.

4) This project is unique as there are no other medical groups assessing this medication with this particular patient population. Since this study involves confidential patient information, volunteer participation is precluded.

C) Project Outcomes and Evaluation

1) The anticipated outcome is a significant reduction in nausea and vomiting for the gynecologic cancer patients receiving chemotherapy for their disease.

2)We will be able to assess our outcomes via cumulative safety and efficacy assessment. This will be based upon an examination of the 120 hours following the first cycle of chemotherapy. Patients will also record the use of rescue therapy (when applicable) and daily nausea

assessments from the initiation of chemotherapy infusion (0 hour) until the morning of day 6 (120 hour) following initial infusion.

3) The study coordinators will be continually meeting with the patients as they receive their chemotherapy. Moreover, the coordinators will assess and corroborate their data with the patients' personal inventory responses and the collection of patient feedback scores via the Functional Living Index-Emesis.

D) How will you use the grant funds?

Clinical trials are notoriously underfunded; thus, we will use the grant funds to offset the expenses not included in the study trial (study coordinator time, continued data collection/analysis and long-term patient follow-up).

III. Project Future

When support from this grant is concluded, the study will continue via the financial generosity of the physicians who comprise the Women's Cancer Research Foundation. This group of doctors is very interested in, and dedicated to, research. They also perpetually collaborate with the researchers in an effort to conduct the clinical research in which the WCRF is intimately involved.

IV. Governance, Executive Leadership and Key Personnel/Staff Qualifications

A) The board of directors is primarily involved with fundraising and since most of them do not possess a medical research background, their involvement in daily research matters is quite passive; they meet bi-annually to discuss the financial direction of the WCRF.

B) Key leadership for this grant and the enrollment of patients in the Emend clinical trial will be under the supervision of WCRF Research Director, Katrina Lopez, CCRC. She has supervised more than 25 different ovarian, endometrial and cervical cancer clinical trials and managed hundreds of clinical trial patients. Dr. John Paul Micha, the Founder and Chairman, is intimately involved in several of the WCRF's ongoing studies. He is joined by five other physicians and researchers, who are also devoted to finding a cure for gynecologic cancer; they include Dr. Lisa Abaid, Dr. John Brown, Dr. Alberto Mendivil, Dr. Bram Goldstein, and Dr. Mark Rettenmaier. All five of these oncology doctors support the WCRF's clinical trials and provide services to all of our patients who are participating in the various clinical trials.

2013 S.L. Gimbel Foundation APPLICATION

V. Project Budget

A) Please provide a detailed line-item budget for your project by completing the table below. Include all sources of funding for the proposed project.

Line Item Description	Line Item Explanation (Formula/equation used as applicable. Example: 40 books @ $100 each = $4000)	Support From Your Agency	Support From Other Funders	Requested Amount From TCF	Line Item Total of Project
	6 cycles (months) of treatment				
Study Coordinator	$125 x 7 visits = $875 x 50 pts. = $43,750	Yes	No	$3000	$43,750
Physician Exams	50 pts. x 7 = 350 exams x $150 per Exam = $52,500	Yes	No	$3000	$52,500
Informed consent & medical History	50 pts @ $150 ea = $7500	Yes	No	$3000	$7,500
Statistician	Statistical review for manuscript $7500	No	No	$3000	$7,500
Senior Research Fellow	Writing of manuscript $10,000	Yes	No	$3000	$10,000
preparation of manuscript					
TOTALS:	$121,250			$15,000	$121,250

VI. Sources of Funding: Please list your current sources of funding and amounts.

Secured/Awarded

Name of Funder: Foundation, Corporation, Government	Amount
See Attached	

Pending

Name of Funder: Foundation, Corporation, Government	Amount	Decision Date
Gimbel Foundation	$15,000	

VII. Financial Analysis

Agency Name: _____
Most Current Fiscal Year (Dates): From 1/1/2011 To: 12/31/2011

This section presents an overview of an applicant organization's financial health and will be reviewed along with the grant proposal. Provide all the information requested on your entire organization. Include any notes that may explain any extraordinary circumstances. Information should be taken from your most recent 990 and audit. Double Check your figures!

Program to Total Expenses Ratio: Percentage of expenses used to support programming versus how much is spent for general management and fundraising. A general rule is that at least 75 percent of total expenses should be used to support programs – the higher the percentage the better.

Program Expenses	/Total Operating Expenses	= Program Expense Ratio
$ 471,797	$ 517,480	91 %

990: Part IX, Column B, Line 25 990: Part IX, Column A, Line 25

Adminstrative Expense (100%-Program Expense ratio) per 990 above	Percentage of Organization's Current Total Budget used for Administration (from cover page)	Differential
9 %	10 %	1 %

If the differential is above (+) or below (-) 10%, provide an explanation:

Quick Ratio: Measures the level of liquidity and measures only current assets that can be quickly turned to cash. A generally standard Quick Ratio equals 1 or more.

Cash	+ Accounts Receivables	/Current Liabilities	= Quick Ratio
$ 3823	$	48,816	1.9

Total assets 96,347

Excess or Deficit for the Year:

Excess or (Deficit) Most recent fiscal year end	Excess or (Deficit) Prior fiscal year end
$<21,737>	$ 50,871

Notes:

Diversity of Funding Sources: A financially healthy organization should have a diverse mix of funding sources. Complete those categories that apply to your organization using figures from your most recent fiscal year.

Funding Source	Amount	% of Total Revenue	Funding Source	Amount	% of Total Revenue
Contributions	$250,910	51	Program Fees	$267,500	54
Fundraising/Special Events	$		Interest Income	$	
Corp/Foundation Grants	$		Other:	$<22,668>	<5>
Government Grants	$		Other:	$	

Notes:

VI. Sources of Funding: Please list your current sources of funding and amounts.

1. W.M. Keck Foundation	$10,000.00
2. Jameson Foundation	$ 5,000.00
3. Arnold Foundation	$10,000.00
4. Marin-Finn Foundation	$ 5,000.00
5. Vitalogy Foundation	$ 5,000.00
6. Carl E. Wynn Foundation	$ 3,500.00
7. Jacob Best Foundation	$ 3,000.00
8. The Ironman Foundation	$ 1,334.59
Total	$42,834.59

2013 S.L. Gimbel Foundation APPLICATION

V. Project Budget

A) Please provide a detailed line-item budget for your project by completing the table below. Include all sources of funding for the proposed project.

Line Item Description	Line Item Explanation (Formula/equation used as applicable. Example: 40 books @ $100 each = $4000)	Support From Your Agency	Support From Other Funders	Requested Amount From TCF	Line Item Total of Project
	6 cycles				
Study Coordinator	$125 x 7 visits = $875 x 50 pts. = $43,750	Yes	No	$3000	
Physician Exams	50 pts. x 7 = 350 exams x $150 per Exam = $52,500	Yes	No	$3000	
Informed consent + medical History	50 pts @ $150 ea = $7500	Yes	No	$3000	
Statistician	Statistical review for manuscript $7500	No	No	$3000	
Senior Research Fellow	Writing of manuscript $10,000	Yes	No	$3000	
Preparation of manuscript					
TOTALS:	$121,250			$15,000	

VI. Sources of Funding: Please list your current sources of funding and amounts.

Secured/Awarded

Name of Funder: Foundation, Corporation, Government	Amount
See Attached	

Pending

Name of Funder: Foundation, Corporation, Government	Amount	Decision Date
n/a		

Janet Rae

To: Janet Rae
Subject: FW: 2012 Foundation Donations

4/3/2012	$ 10,000.00	W.M. Keck Foundation		
4/25/2012	$ 5,000.00	Jameson Foundation		
5/29/2012	$ 10,000.00	Arnold Foundation		
8/16/2012	$ 5,000.00	Marin-Finn Foundation		
9/4/2012	$ 5,000.00	Vitalogy Foundation		
10/30/2012	$ 3,500.00	Carl E. Wynn Foundation		
11/20/2012	$ 3,000.00	Jacob Best Foundation		$ 3,000.00
12/14/2012	$ 1,334.59	The Ironman Foundation		$ 1,334.59

Board of Directors

1. John Paul Micha, M.D. / Founder/ CEO/President / Member
2. Robert Yeary / Chairman / Member
3. Gloria Alkire, Ed.D. / Member
4. Norman Crawford, D.D.S.
5. Jack Evans
6. Joan Rullo
7. Len Rullo
8. John West, M.D.
9. Mark Schley
10. Lynn Thomas
11. Connie Needham

Internal Revenue Service

Date: May 2, 2007

WOMENS CANCER RESEARCH
FOUNDATION
% JOHN PAUL MICHA MD
351 HOSPITAL RD STE 507
NEWPORT BEACH CA 92663-3500 321

Department of the Treasury
P. O. Box 2508
Cincinnati, OH 45201

Person to Contact:
MS. K. HILSON ID# 31-07340
Customer Service Representative
Toll Free Telephone Number:
877-829-5500
Federal Identification Number:
33-0865870

Dear Sir or Madam:

This is in response to your request of May 2, 2007, regarding your organization's tax-exempt status.

In September 2000 we issued a determination letter that recognized your organization as exempt from federal income tax. Our records indicate that your organization is currently exempt under section 501(c)(3) of the Internal Revenue Code.

Our records indicate that your organization is also classified as a public charity under section 509(a)(2) of the Internal Revenue Code.

Our records indicate that contributions to your organization are deductible under section 170 of the Code, and that you are qualified to receive tax deductible bequests, devises, transfers or gifts under section 2055, 2106 or 2522 of the Internal Revenue Code.

If you have any questions, please call us at the telephone number shown in the heading of this letter.

Sincerely,

Michele M. Sullivan

Michele M. Sullivan, Oper. Mgr.
Accounts Management Operations 1

INTERNAL REVENUE SERVICE
P. O. BOX 2508
CINCINNATI, OH 45201

DEPARTMENT OF THE TREASURY

Date: JUN 0 8 2004

Employer Identification Number:
33-0865870
DLN:
17053052831024
Contact Person:
THOMAS C KOESTER
Contact Telephone Number:
(877) 829-5500
Public Charity Status:
509(a)(2)

ID# 31116

GOA CHARITABLE FOUNDATION
351 HOSPITAL RD STE 507
NEWPORT BEACH, CA 92663-0000

Dear Applicant:

Our letter dated SEPTEMBER 25, 2000, stated you would be exempt from Federal income tax under section 501(c)(3) of the Internal Revenue Code, and you would be treated as a public charity, rather than as a private foundation, during an advance ruling period.

Based on the information you submitted, you are classified as a public charity under the Code section listed in the heading of this letter. Since your exempt status was not under consideration, you continue to be classified as an organization exempt from Federal income tax under section 501(c)(3) of the Code.

Publication 557, Tax-Exempt Status for Your Organization, provides detailed information about your rights and responsibilities as an exempt organization. You may request a copy by calling the toll-free number for forms, (800) 829-3676. Information is also available on our Internet Web Site at www.irs.gov.

If you have general questions about exempt organizations, please call our toll-free number shown in the heading between 8:00 a.m. - 6:30 p.m. Eastern time.

Please keep this letter in your permanent records.

Sincerely yours,

Lois G. Lerner
Director, Exempt Organizations
Rulings and Agreements

Letter 1050 (DO/CG)

The Community Foundation

Serving the Counties of Riverside and San Bernardino

S. L. Gimbel Foundation Fund

BOARD OF DIRECTORS

James Cuevas
Chair of the Board

Philip Savage, IV
Vice Chair of the Board

Pat Spafford, CPA
Chief Financial Officer

Kirk Harns
Secretary of the Board

Glenda Bayless

Sergio Bohon

Rabbi Hillel Cohn

Henry Coil
Past Board Chair

Andrea Dutton

Robert Fey

Paul Granillo

Stanley Grube

Dr. Albert Karnig

Vernon Kozlen

D. Matthew Pim

Patrick O'Reilly

Benita B. Roberts

Rose Salgado

Beverly Stephenson

Grover Trask
Immediate Past Board Chair

Sean Varner

Dr. Jonathan Lorenzo Yorba
President and CEO

October 21, 2013

Dr. John Paul Micha, M.D.
President & CEO
Nancy Yeary Women's Cancer Research Foundation
351 Hospital Rd, Suite 506
Newport Beach, CA 92663

Dear Dr. Micha:

Congratulations! A grant has been approved for **Nancy Yeary Women's Cancer Research Foundation** in the amount of **$15,000** from the S.L. Gimbel Foundation. The performance period for this grant is November 1, 2013 to October 31, 2014. Additional funding beyond the performance period is not guaranteed. It is highly recommended that alternative funding sources be sought accordingly. The grant is to support the following as specified in your proposal:

Gynecological Cancer Research: Assist funding for gynecological cancer research.

This grant is subject to the terms outlined in the enclosed Grant Agreement. After you have reviewed the terms and conditions of the Grant Agreement, please sign and date the enclosed copy and return the original copy to The Community Foundation within the next two weeks. Please retain a copy of the signed agreement for your records. Funds will be released upon receipt of the signed Grant Agreement.

A condition of this grant is that you agree to submit the Grant Evaluation Form which includes a narrative report and fiscal report. The Grant Evaluation is due on November 15, 2014 and a copy will be included with the check cover letter.

We wish you great success and look forward to working with you during the grant performance period.

If you have any questions, please call me at 951-684-4192 ext. 114 or email me at ccudiamat@thecommunityfoundation.net.

Sincerely,

Celia Cudiamat
Executive Vice President

20000 Nancy Yeary Women's Cancer Research Foundation 20130711
GIMB3

NATIONAL STANDARDS

ned in Compliance
ational Standards for
ommunity Foundations

3700 Sixth Street, Suite 200 ~ Riverside, California 92501
P: 951.241.7777 ~ F: 951.684.1911 ~ www.thecommunityfoundation.net

10/30/13

The Community Foundation
Serving the Counties of Riverside and San Bernardino

3700 Sixth Street, Suite 200
Riverside, CA 92501
v) 951-684-4194 f) 951-684-1911
www.thecommunityfoundation.net

2013 S.L. Gimbel Foundation Fund

Grant Agreement

Organization: **20000 Nancy Yeary Women's Cancer Research Foundation**

Grant Amount: **$ 15,000** **Grant Number:** **20130711**

Grant Period: **November 1, 2013 to October 31, 2014**

Purpose: **Gynecological Cancer Research: Assist funding for gynecological cancer research**

1. Use of Grant Funds
Grant funds must be expended within the grant period, for the purpose and objectives described in your grant proposal. Grant funds may not be expended for any other purpose without prior written approval by The Community Foundation. If there are significant difficulties in making use of the funds as specified in your proposal, or if the grant funds cannot be spent within the grant period, notify us in writing promptly.

Formal requests for extensions or variances must be submitted to the Foundation's Board of Directors for approval a minimum of 60 days before the end of the grant period.

Requests for variances or extensions are reviewed on a case-by-case basis and approved by the Board of Directors. If a request is denied, unused funds must be immediately refunded to the Foundation.

2. Payment of Grant Funds
The grant funds will be paid in full by the Foundation upon receipt of the signed Grant Agreement. Challenge grant funds will be paid in full upon receipt of the signed Grant Agreement and upon receipt of documentation providing evidence that condition(s) of the challenge grant has/have been met.

3. Certification and Maintenance of Exempt Organization Status
This grant is specifically conditioned upon Grantee's status as an eligible grantee of The Community Foundation. The Foundation has obtained a copy of the Grantee's IRS determination letter. Grantee confirms that it has not had any change in its tax-exempt status, and shall notify the Foundation immediately of any such change.

4. Final Report and Records
The Grantee will submit the Grant Evaluation report per the deadline set forth in the award letter. This report includes a narrative on outcomes based on goals and objectives set forth in the grant proposal and an expenditure report documenting use of grant funds. If equipment was purchased, copies of receipts need to be included.

5. Grantee's Financial Responsibilities
Grantee will keep records of receipts and expenditures of grant funds and other supporting documentation related to the grant at least four (4) years after completion of the grant and will make such records of receipts, expenditures and supporting documentation available to the Foundation upon request.

6. Publicity
The Community Foundation expects publicity for the grant in two ways and will require documentation in your grant evaluation form that you will file at the end of the grant period.

1. *Organizational:* Acknowledge The Community Foundation in internal communication to staff and board, in brochures as appropriate; newsletters, annual reports and email blasts or e-newsletters.

2. *Press:* Publicity for The Community Foundation grant via press releases to local media.

The credit line of "Made possible in part by a grant from the **"S.L. Gimbel Foundation Advised Fund at The Community Foundation Serving the Counties of Riverside and San Bernardino"** is suggested. When your donors are listed in printed materials, include the S.L. Gimbel Foundation Advised Fund at The Community Foundation in the appropriate contribution size category. When publishing our name, please note the "The" at the beginning of our name is a legal part of our name. It should always be used and capitalized. Attaching our logo is also appreciated. Our logo can be downloaded from our website at www.thecommunityfoundation.net.

7. Indemnification

In the event that a claim of any kind is asserted against the Grantee or the Foundation related to or arising from the project funded by the Grant and a proceeding is brought against the Foundation by reason of such claim, the Grantee, upon written notice from the Foundation, shall, at the Grantee's expense, resist or defend such action or proceeding, at no cost to the Foundation, by counsel approved by the Foundation in writing.

Grantee hereby agrees, to the fullest extent permitted by law, to defend, indemnify, and hold harmless the Foundation , its offices, directors, employees, and agents, from and against any and all claims, liabilities, losses, and expenses (including reasonable attorneys' fees) directly, indirectly, wholly, or partially arising from or in connection with any act or omission by Grantee, its employees, or agents in applying for or accepting the Grant, in expending or applying the Grant funds or in carrying out any project or program supported by the Grant, except to the extent that such claims, liabilities, losses, and expenses arise from or in connection with any bad faith act or omission by the Foundation, its officers, directors, employees, or agent.

8. Termination

The Community Foundation may terminate this agreement, withhold payments, or both at any time, if, in the Community Foundation's judgment: a) The Community Foundation is not satisfied with the quality of the Grantee's progress toward achieving the project goals and objectives; b) the Grantee dissolves or fails to operate; c) the Grantee fails to comply with the terms and conditions of this agreement.

9. Limitation of Support

This Agreement contains the entire agreement between the parties with respect to the Grant and supersedes any previous oral or written understandings or agreements.

****

I have read and agree to the terms and conditions of the Grant Agreement.

X John Paul Micha MD
Signature

X 10/23/13
Date

X JOHN PAUL MICHA, M.D.
Printed Name

X President
Title

Organization: 20000 Nancy Yeary Women's Cancer Research Foundation
Grant Number: 20130711

10/30/13

The Community Foundation

Serving the Counties of Riverside and San Bernardino

S. L. Gimbel Foundation Fund

BOARD OF DIRECTORS

James Cuevas
Chair of the Board

Philip Savage, IV
Vice Chair of the Board

Pat Spafford, CPA
Chief Financial Officer

Kirk Harns
Secretary of the Board

Glenda Bayless

Sergio Bohon

Rabbi Hillel Cohn

Henry Coil
Past Board Chair

Andrea Dutton

Robert Fey

Paul Granillo

Stanley Grube

Dr. Albert Kamig

Vernon Kozlen

D. Matthew Pim

Patrick O'Reilly

Benita B. Roberts

Rose Salgado

Beverly Stephenson

Grover Trask
Immediate Past Board Chair

Sean Varner

Dr. Jonathan Lorenzo Yorba
President and CEO

November 6, 2013

Mr. John Paul Micha M.D.
President & CEO
Nancy Yeary Women's Cancer Research Foundation
351 Hospital Rd, Suite 506
Newport Beach, CA 92663

Dear Mr. Micha

The Community Foundation is pleased to enclose a grant check for **$15,000** from the S. L. Gimbel Foundation, a component fund at The Community Foundation. By cashing the grant check, you are agreeing to the conditions stated under the *Terms of Grant* which you have signed and returned. The completed Grant Evaluation form is due by November 15, 2014 and is enclosed. Please note that any grant variances or extensions must be requested in writing and in advance. Any remaining grant funds must be returned to The Community Foundation at the end of the grant period.

We greatly appreciate any help you can give us in publicizing the grant. **Please use the following credit in any grant announcements or materials funded by the grant: "The (name of project/program) is supported by a grant from The S. L. Gimbel Foundation".** Send copies of articles printed in local papers, stories in your agency newsletter, annual report, press releases, and other publications for our files.

If you have any questions, please contact me at 951 684-4194.

Sincerely,

Celia Cudiamat
Executive Vice President

20130711 *36246* *GIMB*

Encl: Grant Evaluation

HOLD TO LIGHT TO VIEW WATERMARK IN PAPER HEAT SENSITIVE RED IMAGE DISAPPEARS WITH HEAT DETECTION CIRCLE REVEALS A LOCK WHEN TESTED

36246

The Community Foundation
Serving the Counties of Riverside and San Bernadino

3700 SIXTH STREET, SUITE 200
RIVERSIDE, CA 92501
951-241-7777 / FAX 951-684-1911

CITIZENS BUSINESS BANK
A Financial Services Company
3695 Main Street, Riverside, CA 92501
90-3414-1222

EZShield® Check Fraud Protection for Business

VOID VOID VOID

PAY * Fifteen Thousand and no/100 *

DATE 10/31/2013

AMOUNT $****15,000.00

TO THE ORDER OF

Nancy Yeary Women's Cancer Research Foundation
351 Hospital Rd, Suite 506
Newport Beach, CA 92663

AUTHORIZED SIGNATURE

Security features. Details on back.

⑈036246⑈ ⑆122234649⑆ 244124437⑈

36246

The Community Foundation

20000 Nancy Yeary Women's Cancer Research Foundation 10/31/2013 036246

20130711	10/18/2013	Gynecological Cancer Research		15,000.00
GIMB		S.L. Gimbel Foundation Advised Fund	15,000.00	

CHECK TOTAL: $****15,000.00

36246

The Community Foundation

20000 Nancy Yeary Women's Cancer Research Foundation 10/31/2013 036246

20130711	10/18/2013	Gynecological Cancer Research		15,000.00
GIMB		S.L. Gimbel Foundation Advised Fund	15,000.00	

CHECK TOTAL: $****15,000.00

PRODUCT SSLT111 USE WITH 91500 ENVELOPE PRINTED IN U.S.A. A